6JU0 Stock Overview
A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
My Notes
Capture your thoughts, links and company narrative
BioCardia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.78 |
| 52 Week High | US$18.45 |
| 52 Week Low | US$0.15 |
| Beta | 1.36 |
| 1 Month Change | 0% |
| 3 Month Change | 12.24% |
| 1 Year Change | -56.03% |
| 3 Year Change | -86.99% |
| 5 Year Change | n/a |
| Change since IPO | -81.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6JU0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -2.0% |
| 1Y | -56.0% | -13.2% | 6.8% |
Return vs Industry: 6JU0 underperformed the German Biotechs industry which returned -19.7% over the past year.
Return vs Market: 6JU0 underperformed the German Market which returned 4.9% over the past year.
Price Volatility
| 6JU0 volatility | |
|---|---|
| 6JU0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6JU0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6JU0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Peter Altman | www.biocardia.com |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
BioCardia, Inc. Fundamentals Summary
| 6JU0 fundamental statistics | |
|---|---|
| Market cap | €5.27m |
| Earnings (TTM) | -€7.66m |
| Revenue (TTM) | €383.23k |
13.7x
P/S Ratio-0.7x
P/E RatioIs 6JU0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6JU0 income statement (TTM) | |
|---|---|
| Revenue | US$428.00k |
| Cost of Revenue | US$5.07m |
| Gross Profit | -US$4.64m |
| Other Expenses | US$3.92m |
| Earnings | -US$8.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.03 |
| Gross Margin | -1,084.35% |
| Net Profit Margin | -1,999.77% |
| Debt/Equity Ratio | 0% |
How did 6JU0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/27 20:18 |
| End of Day Share Price | 2024/05/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioCardia, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Emanuela Branchetti | H.C. Wainwright & Co. |